Pegsebrenatide
Metabolic / fat loss
Appetite, glucose, weight, and metabolic regulation
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Incretin / metabolic peptide or small molecule
- Primary mechanism
- Incretin/amylin/glucagon-axis receptor modulation
- Primary market use
- Metabolic / fat loss
Pharmacology
- Oral bioavailability
- Route-dependent / verify
- Half-life
- ~1–7 days (half-life-extended peptide class estimate)
- Route tags
- SubQ; Injectable; route-dependent
- Evidence level
- MCE product listing / research chemical signal
- Clinical status
- Research chemical/reference listing
- Value-for-money score
- 8 / 10
Reported protocol signal
No clean popular protocol found in uploaded sources; create as research/reference entry and verify before public protocol display.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Stackability
Commonly compared/stacked in metabolic and body-composition protocols; verify redundancy and risk.
Notes
Pegsebrenatide (NLY01) is a blood-brain barrier-penetrant GLP-1R agonist. Pegsebrenatide alleviates retinal inflammation and neuronal death secondary to ocular hypertension . Pegsebrenatide significantly delays onset and reduces disease severity in experimental autoimmune encephalomyelitis . Pegsebrenatide inhibits the formation of A1 reactive astrocytes in nerve cells and reduces the loss of retinal ganglion cells and dopaminergic neurons. Pegsebrenatide exerts neuroprotective effects in a mous...